<P> Wockhardt is the first company outside the US and Europe to manufacture recombinant human insulin . </P> <P> Wockhardt's acquisitions include Wallis Laboratory, UK (1998), Merind, India (1998), CP Pharmaceuticals, UK (2003), Espharma GmbH, Germany (2004), Dumex India (2006), Pinewood Laboratory, Ireland (2006), Morton Grove, US (2007), and Negma, France (2007). Wockhardt's debt following the acquisitions was close to Rs 38 billion, and Habil Khorakiwala quit as managing director . The board of directors, on 31 March 2009 approved the appointments of Habil Khorakiwala's sons Murtaza Khorakiwala and Hozaifa Khorakiwala as managing director and Executive Director respectively </P> <P> As of April 28, 2017, the consensus forecast amongst 2 polled investment analysts covering Wockhardt Limited advises that the company will underperform the market . This has been the consensus forecast since the sentiment of investment analysts deteriorated on November 17, 2016 . The previous consensus forecast advised investors to hold their position in Wockhardt Limited . </P>

When did wockhardt go public (listed on stock exchange)